Answer Summary

Members overwhelmingly expressed enthusiasm about the prospect of a twice-yearly HIV treatment, with many citing the appeal of fewer pills,... Read more

Members overwhelmingly expressed enthusiasm about the prospect of a twice-yearly HIV treatment, with many citing the appeal of fewer pills, reduced worry about forgetting doses, and greater convenience, though several noted disappointment that the new option still requires daily antiretroviral medication in combination. Many members shared their positive experiences with bimonthly Cabenuva injections, reporting improved CD4 counts, maintained undetectable viral loads, and relief from daily pill fatigue, while others expressed cautious optimism tempered by concerns about side effects, medication interactions, and whether their doctors would recommend the switch. A recurring theme was frustration with the slower pace of HIV treatment innovation in the United States compared to Europe, alongside hope that newer, less frequent treatment options will eventually become accessible to all, not just those with medication resistance.